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Abstract
Introduction: Over 5,000 cases of invasive Candida species infections occur in the United Kingdom each year, and
around 40% of these cases occur in critical care units. Invasive fungal disease (IFD) in critically ill patients is
associated with increased morbidity and mortality at a cost to both the individual and the National Health Service.
In this paper, we report the results of a systematic review performed to identify and summarise the important risk
factors derived from published multivariable analyses, risk prediction models and clinical decision rules for IFD in
critically ill adult patients to inform the primary data collection for the Fungal Infection Risk Evaluation Study.
Methods: An internet search was performed to identify articles which investigated risk factors, risk prediction
models or clinical decisions rules for IFD in critically ill adult patients. Eligible articles were identified in a staged
process and were assessed by two investigators independently. The methodological quality of the reporting of the
eligible articles was assessed using a set of questions addressing both general and statistical methodologies.
Results: Thirteen articles met the inclusion criteria, of which eight articles examined risk factors, four developed a
risk prediction model or clinical decision rule and one evaluated a clinical decision rule. Studies varied in terms of
objectives, risk factors, definitions and outcomes. The following risk factors were found in multiple studies to be
significantly associated with IFD: surgery, total parenteral nutrition, fungal colonisation, renal replacement therapy,
infection and/or sepsis, mechanical ventilation, diabetes, and Acute Physiology and Chronic Health Evaluation II
(APACHE II) or APACHE III score. Several other risk factors were also found to be statistically significant in single
studies only. Risk factor selection process and modelling strategy also varied across studies, and sample sizes were
inadequate for obtaining reliable estimates.
Conclusions: This review shows a number of risk factors to be significantly associated with the development of
IFD in critically ill adults. Methodological limitations were identified in the design and conduct of studies in this
area, and caution should be used in their interpretation.
Introduction
In the past, invasive fungal disease (IFD) was more com-
monly found in patients who were neutropenic, had
received a solid organ transplant or had been treated
with corticosteroids or cytotoxic agents. Increasingly,
IFD is now more likely to occur in nonneutropenic
patients in critical care units [1]. The majority of IFD in
the critical care setting is due to Candida species [2,3].
In 2006, the Health Protection Agency (HPA) estimated
that over 5,000 cases of invasive Candida species infec-
tions occur in the UK each year and that around 40% of
these occur in critical care units [4]. An epidemiological
survey in six UK sentinel hospitals reported that 45% of
Candida bloodstream infections occur in the critically ill
[5]. IFD in critically ill patients is associated with
increased morbidity and mortality at a cost to both the
individual and the National Health Service [6,7].
A number of randomised controlled trials (RCTs) have
evaluated antifungal prophylaxis in nonneutropenic, cri-
tically ill patients, predominantly with either fluconazole
[8-12] or ketoconazole [13-16]. Several systematic
reviews and meta-analyses of these studies have been
performed [17-22]. These reviews reveal that, across the
individual studies, patient groups were heterogeneous,
ranging from high-risk surgical patients [11,12,16] to
those with septic shock [8] or acute respiratory distress
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were at high risk of IFD, with rates in the control arms
typically being over 10%. Despite this heterogeneity, the
RCTs demonstrated a remarkably homogeneous effect
of antifungal prophylaxis on the risk of proven IFD with
a suggested reduction in all-cause mortality [17]. The
question, therefore, is not whether antifungal prophy-
laxis is effective, but rather how to select an appropriate
group of high-risk patients to receive prophylaxis, as
indiscriminate use of antifungal agents is likely to pro-
mote drug resistance and drive up cost.
The Fungal Infection Risk Evaluation (FIRE) Study
was undertaken with the aim of developing and validat-
ing a risk model to identify critically ill nonneutropenic
patients at high risk of IFD who would benefit from
antifungal prophylaxis (UK Clinical Research Collabora-
tion registered ID number 42) [https://www.icnarc.org/
CMS/ArticleDisplay.aspx?ID=8234e564-5902-de11-b27f-
0015c5e673e7&root=RESEARCH&categoryID=70422f67-
6983-de11-9a46-002264a1a658]). The first step in model
development was to prospectively gather data on risk
factors for IFD for this patient group. This paper reports
the results of a systematic review performed to identify
and summarise the important risk factors from pub-
lished multivariable analyses, risk prediction models and
clinical decision rules for IFD in critically ill adult
patients to inform the primary data collection in the
FIRE Study.
Materials and methods
An internet search was performed using MEDLINE
(1950 to 2008, SilverPlatter WebSPIRS, http://www.ovid.
com/site/products/tools/silverplatter/sp_webspirs.jsp;
Ovid/Wolters Kluwer Health, New York, NY, USA),
Embase (1947 to 2008, http://www.embase.com/; Silver-
Platter WebSPIRS) and CINAHL (1960 to 2008, EBSCO-
host, http://www.ebscohost.com/cinahl/; EBSCO
Publishing, Ipswich, MA, USA) to identify published
English-language articles which (1) investigated the pre-
dictive value of risk factors for IFD in critically ill adult
patients, or (2) developed or evaluated a risk score or
risk prediction model for IFD in critically ill adult
patients or (3) developed or evaluated a clinical decision
rule or patient algorithm for use of antifungal prophy-
laxis in critically ill adult patients. Three search phrases
were combined: ‘fungal disease and treatment’, ‘patient
population’ and ‘risk factors/risk models/clinical rules’
(see Additional file 1 for search strategy).
Articles were identified in a staged process whereby
titles were initially screened for potential eligibility by a
single reviewer (GE). Abstracts and full texts of those
potentially eligible were then assessed by two reviewers
(HM and JS) independently and were included if the fol-
lowing criteria were met: (1) evaluation of multiple risk
factors, a scoring system or a clinical decision rule for
IFD in critically ill patients; (2) inclusion of a control
group consisting of patients without IFD or any other
systemic infection and (3) study of adult humans (age >
18 years). Any disagreements between the reviewers
were resolved by a third (DH). Following review of
abstracts, we obtained full-text articles for all that were
eligible for inclusion. At this point, members of the
FIRE Study Steering Group (see Acknowledgements), as
clinical experts in the field, were contacted to determine
if any relevant articles were missed.
Data were extracted onto standardised data extraction
sheets independently by two reviewers (HM and JS; data
extraction sheets available on request). The following
data were abstracted from each article: study design,
method of data collection, clinical setting, population
characteristics, method of analysis, risk factors reported,
outcome (types and definitions of IFD) and strength of
association demonstrated. Data were gathered on the
adjusted ORs, 95% CIs, and P-values for each of the stu-
died risk factors.
The methodological quality of the reporting of the
selected articles was assessed independently by two
reviewers (HM and JS) using a set of questions addres-
sing both general and statistical methodologies. Given
that no gold standard method exists for the methodolo-
gical assessment of risk factor studies, the questions
were drawn from research from a published quality
assessment method for randomised and nonrandomised
studies [23], as well as from research on reporting of
prognostic models in the oncology field [24,25].
Eight questions assessed the general methodology:
study objectives, outcome description, patient character-
istics, number of centres recruited, existence of an a
priori analysis plan, adjustment for known risk factors,
rationale behind risk factor inclusion and definition of
risk factors. In assessing whether study results were
adjusted for known risk factors, the factors considered
were severity of illness, length of stay, antibiotics use,
receipt of total parenteral nutrition, immunosuppressant
use, diabetes, renal dysfunction or renal replacement
therapy, central venous catheter use and major surgery.
These risk factors were selected based on expert clinical
opinion. A study was recorded as adjusting for a major-
ity of the known risk factors if six or more of the nine
risk factors were accounted for.
Three questions assessed the statistical methodology:
adequacy of sample size, risk factor selection and model
strategy choice. Adequacy of sample size was established
using the generally held rule of ten events per variable
[25]. All risk factors included in the statistical modelling,
including those excluded from multivariable modelling
following univariable screening, were included in the
calculation of events per variable. ‘Risk factor selection’
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variable logistic regression model. The selection process
was based on univariable analysis, previous literature or
investigator choice, or no selection strategy, whereby all
risk factors were entered into the model. ‘Model strat-
egy’ consisted of either forward selection, backward
elimination or no stepwise process, whereby all risk fac-
tors were kept in the model. If details on the risk factor
selection and model strategy were absent, then they
were labelled as unclear.
Results
The electronic search identified a total of 1,864 citations
(Figure 1). After screening of titles, 165 articles were
selected for abstract and full-text review, and 152 of
these that were potentially eligible were excluded
because they failed to meet the inclusion criteria.
Among these, 109 did not assess multiple risk factors, a
scoring system and/or a clinical decision rule; 122
articles had a control group which had a systemic infec-
tion; and 5 were not adult human studies. Some articles
were excluded for multiple reasons. No additional arti-
cles were identified by the clinical experts consulted.
The 13 articles that met the inclusion criteria fell into
three groups: 8 articles examined risk factors, 4 devel-
oped a risk prediction model or clinical decision rule
and 1 was an evaluation of a clinical decision rule. Two
of the articles utilised data from the same study: the
EPCAN Study [26,27]. There were three case-control
and nine cohort studies with varying inclusion criteria,
including age and length of stay in the critical care unit.
The studies were conducted in various countries: Brazil,
France, Greece, Spain, Sweden, Switzerland and the
USA. Six were based on general critical care patients,
and the patients in the rest of the articles were selected
from specialised units, including surgical, cardiac and
trauma units. Studies varied greatly in terms of outcome
definitions. Four studies reported only on Candida
may have more than one reason for exclusion
152 articles excluded
Į:
¾  109 articles did not compare 
multiple risk factors, risk prediction 
models or clinical decision rules 
¾  122 articles had a control group 
which had a systemic infection 
¾  5 articles were in either animals or 
in non adults
1,696 excluded 
on screening 
1,864 records identified through 
database searching 
165 articles assessed for eligibility 
13 articles included in review 
(12 studies) 
Figure 1 Article flow through different stages of the review. a = Articles may have more than one reason for exclusion.
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Research and Treatment of Cancer/Invasive Fungal
Infections Cooperative Group and the National Institute
of Allergy and Infectious Diseases Mycoses Study Group
(EORTC/MSG) criteria or modifications thereof, and
the rest used alternative definitions. Given the heteroge-
neity of the studies, no meta-analysis was performed.
The general characteristics of the selected studies are
shown in Table 1.
Analysis of risk factors
The risk factors examined varied between the studies.
T a b l e2r e p o r t sa l lt h er i s kf actors that were identified
as statistically significantly associated with IFD in one or
more of the 10 studies (11 articles) that carried out a
multivariable analysis. Table 3 reports all significant risk
factors that were examined, and the number of studies
in which these were associated with IFD, on univariable
and multivariable analyses. Candidate risk factors, in
descending order of the number of studies in which the
risk factor was significantly associated on multivariable
analysis, are described below.
Surgery
Seven studies [26-33] examined the association between
surgery and IFD. The type and timing of surgery varied
across the studies, with two [28,30] looking at abdom-
inal surgery and the others looking at any surgical pro-
cedure. Five of the seven studies [26-30,32] reported a
significant association between surgery and IFD on both
univariable and multivariable analyses.
Total parenteral nutrition
Six of the twelve studies [26,27,29,30,32,34,35] assessed
total parenteral nutrition as a risk factor, and all found a
significant association with IFD on univariable analysis.
Of the six studies, four [26,27,29,30,34] also found a sig-
nificant association on multivariable analysis.
Fungal colonisation
Five studies [26-29,31,33] examined the association
between fungal colonisation and IFD. Four of the five
studies [26-28,31,33] reported an association on both
univariable and multivariable analyses. The sites of fun-
gal colonisation examined and modelling approaches
varied across the studies.
Renal replacement therapy
Seven studies [26,27,30,32-36] examined renal replace-
ment therapy as a risk factor for IFD, of which five
[26,27,30,32,34,35] found a significant association on
univariable analysis. Three studies [26,30,35] demon-
strated a significant association on multivariable analysis.
Only one of the two EPCAN articles demonstrated a
significant result on multivariable analysis. The type and
exposure time to dialysis varied across the studies. Some
looked at preadmission dialysis, and others examined
haemofiltration in the unit.
Infection and sepsis
Five studies [27,29,30,33,36] examined the relationship
between infection and sepsis and IFD, three [27,30,36]
of which demonstrated an association on multivariable
analysis. The source and site of infection varied across
the studies. One examined bacterial infection and bac-
teraemia without specifying type and source of infection
[36]. Another examined enteric bacteraemia, which
included Enterococcus, Bacteroides and other Gram-
negative bacilli bloodstream infections [30]. One demon-
strated an association with severe sepsis, although the
infection source was not specified [27].
Mechanical ventilation
Five studies [26,27,29,32,34,36] examined the association
between receipt of mechanical ventilation and IFD. Two
of the five studies [32,36] reported a significant associa-
tion on multivariable analysis. Both timing and duration
of mechanical ventilation varied across the studies, with
one study examining mechanical ventilation on day 3 of
critical care unit admission [32] and the other on day 10
[36].
Diabetes
Four studies [27,28,35,36] examined whether a medical
history of diabetes mellitus was a risk factor for IFD.
Two of the four studies [35,36] demonstrated a signifi-
cant association on both univariable and multivariable
analyses.
APACHE II or APACHE III score
Eight studies [26-29,31,33-35] examined whether either
the Acute Physiology and Chronic Health Evaluation II
(APACHE II) score or APACHE III score was a risk fac-
tor for IFD. Two [31,33] of the eight studies demon-
strated a significant association on both univariable and
multivariable analyses.
Other risk factors
A number of other risk factors were identified as being
significantly associated with IFD on multivariable analy-
sis in single studies. These included cardiopulmonary
bypass time, acute renal failure, broad-spectrum antibio-
tic use, red blood cell transfusions, antifungal medica-
tion use, central venous catheter use, diarrhoea and
peripheral catheter use (Table 2). Of note, two studies
[26,37] examined the association between neutropenia
and IFD, neither of which demonstrated a significant
association. Similarly, none of the five studies
[27,28,33-35] looking at immunosuppressant use
demonstrated an association with IFD.
Risk prediction models and clinical decision rules
Four of the studies developed a risk prediction model or
clinical decision rule (Table 4), and one evaluated a clin-
ical decision rule for IFD, all in the critical care setting.
León et al. [27] developed and validated a risk predic-
tion model from which they derived a bedside scoring
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Study Study type Selection criteria Study
design
Number
of ICUs
Total
patients
Patients
with
outcomes/
cases
Outcome/case definition
Agvald-Ohman
et al., 2008 [28]
Risk factor
analysis
Any multidisciplinary ICU
patients
LOS ≥ 7 days
Prospective
cohort
1 59 10 Blood and/or sterile body site
culture positive for Candida
species
Blumberg et
al., 2001 [29]
Risk factor
analysis
SICU patients
LOS > 48 hours
Prospective
cohort
6 4,276 42 Candida species recovered from
culture of blood specimen
collected > 48 hours after
admission to SICU
Borzotta &
Beardsley, 1999
[34]
Risk factor
analysis
Trauma ICU patients
Cases selected if LOS > 4
days, age > 16 years and any
evidence of fungal infection
or treatment
Controls matched for sex,
mechanism of injury, age
and Injury Severity Score
Controls selected at 2:1 ratio
Case-control 1 656 20 Blood culture positive for yeast
infection
Yeast from any sterile area
Funguria with signs of sepsis and
no bacterial pathogen source if >
105 colonies/ml yeast
Candida growth at two sites with
fever and WBC count > 12,000/μl
and no bacterial isolates within
48 hours
Chow et al.,
2008 [30]
Risk factor
analysis
Medical or SICU patients
Cases selected if positive
blood culture for Candida
species after the first 48
hours of admission to unit
Controls matched for study
hospital, ICU type and
admission date
Controls selected at 5:1 ratio
Case-control 2 926 146 At least one blood culture
positive for Candida species
Ibàñez-Nolla et
al., 2004 [31]
Risk factor
analysis
Any multidisciplinary ICU
patients
Candida species in culture or
on histological examination
during ICU stay or
postmortem
Neutrophil count ≥ 500/mm
3
Prospective
cohort
1 145 120 Multifocal candidiasis:
simultaneous isolation of Candida
species in two or more of the
following locations: respiratory,
digestive or urinary tract or other
locations
or
Disseminated candidiasis, yeasts
in fluids from sterile sites or
histological samples from deep
organs or diagnosis of
endophthalmitis or candidaemia
with negative catheter tip
cultures
Also, use of EORTC/MSG
guidelines
Jordà-Marcos
et al.,
2007 [26]
a
Risk factor
analysis
Any multidisciplinary ICU
patients
Age > 18 years
LOS ≥ 7 days
Prospective
cohort
73 1,765 63 At least one blood culture
positive for Candida species
León et al.,
2006 [27]
a
Development
of risk
prediction
model
Multidisciplinary ICU patients
Age > 18 years
LOS ≥ 7 days
Only patients with fungal
colonisation included in risk
factor analysis/model
development
Prospective
cohort
73 1,699 97 Candidaemia
Candidal endophthalmitis in a
patient with clinical sepsis
Candida species from sterile sites
Histologically documented
candidiasis
Michalopoulos
et al., 2003 [36]
Risk factor
analysis
Cardiothoracic ICU patients
Cases selected if at least one
blood culture positive for
Candida species detected
Controls matched for
admission date, gender, BMI,
sedatives, CPB technique and
cardioplegia type
Controls selected at 4:1 ratio
Case-control 1 150 30 At least one blood culture
positive for Candida species
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tropenic critically ill patients. The study comprised a
prospective cohort of 1,699 patients, of whom 980 with
colonisation or infection were included in the model
development with 97 IFDs. Multifocal Candida coloni-
sation, surgery directly prior to critical care unit admis-
sion, severe sepsis and total parenteral nutrition were
included in the final risk prediction model. The optimal
score from the model gave a sensitivity of 81% and a
specificity of 74%.
Ostrosky-Zeichner et al. [37] developed a number of
clinical decision rules for IFD in the critical care setting.
Their study was a retrospective chart review of 2,890
patients from 12 participating centres with 88 cases of
IFD. Several clinical decision rules, with varying combi-
nations of risk factors, were developed and tested. The
best-performing rule consisted of the following risk fac-
tors: any systemic antibiotic, presence of a central
venous catheter. In addition, their rule included at least
two of the following risk factors: total parenteral nutri-
tion, any dialysis, any major surgery, pancreatitis and
Table 1 Characteristics of selected studies (Continued)
McKinnon et
al., 2001 [32]
Risk factor
analysis
SICU patients
LOS ≥ 5 days
Age > 18 years
Prospective
cohort
3 301 27 Colonisation of two or more sites
or candidaemia
Ostrosky-
Zeichner et al.,
2007 [37]
Development
of clinical
decision rule
Multidisciplinary ICU patients
Age ≥ 19 years
LOS ≥ 4 days
No evidence of invasive
candidiasis or systemic
antifungal use in week prior
to ICU admission through
first 3 days of admission
Retrospective
cohort
12 2,890 88 EORTC/MSG criteria
Paphitou et al.,
2005 [35]
Development
of clinical
decision rule
SICU patients
LOS ≥ 4 days
Retrospective
cohort
1 327 36 Based on proven, probable or
possible cases
Criteria modelled on EORTC/MSG
criteria
Piarroux et al.,
2004 [38]
Evaluation of
clinical
decision rule
SICU patients
LOS ≥ 5 days
Excluded liver transplants
Prospective
and
retrospective
cohorts
1 933 50 EORTC/MSG criteria
Pittet et al.,
1994 [33]
Risk factor
analysis and
development
of clinical
decision rule
SICU/neonatal ICU patients
Candida colonisation in three
or more samples on two
consecutive days
Prospective
cohort
2 29 11 Candidaemia
or
One blood culture with one
histologically documented
invasive candidiasis
or
Ophthalmic examination
consistent with candidal
endophthalmitis
or
At least two blood cultures taken
at different times
or
One peripheral blood culture and
one central line blood culture
showing identical Candida
species
or
Severe nonbloodstream Candida
species infection
Candida species in normally
sterile site and at least one of the
following:
Fever or hypothermia
Unexplained, prolonged
hypotension
No response to adequate
antibiotic treatment for a
suspected bacterial infection
BMI = body mass index; CPB = cardiopulmonary bypass; EORTC/MSG = European Organization for Research and Treatment of Cancer/Invasive Fungal Infections
Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group; LOS = length of stay; SICU = surgical ICU.
aArticles from
the EPCAN Study.
Muskett et al. Critical Care 2011, 15:R287
http://ccforum.com/content/15/6/R287
Page 6 of 15Table 2 Risk factors and adjusted effect estimates
Risk factors Studies OR (95% CI) P-values
Surgery
General abdominal surgery Agvald-Ohman et al., 2008 [28] 60.7 (7.3 to infinity) 0.0013
Any surgery Blumberg et al., 2001 [29] 7.3 (1 to 53.8) 0.05
Elective surgery Jordà-Marcos et al., 2007 [26]
a 2.75 (1.17 to 6.45) 0.02
Surgery on ICU admission León et al., 2006 [27]
a 2.71 (1.45 to 5.06) < 0.001
Gastrointestinal procedure Chow et al., 2008 [30] 2.24 (1.49 to 3.38)
b < 0.001
b
Major pre-ICU operation Chow et al., 2008 [30] 2.12 (1.14 to 3.97)
b 0.02
b
Major operation during ICU stay Chow et al., 2008 [30] 1.26
a 0.04
a
Multiple surgical procedures McKinnon et al., 2001 [32] NR ≤ 0.05
Total parenteral nutrition
Total parenteral nutrition duration/days at risk Chow et al., 2008 [30] 11 (5.52 to 21.7)
a < 0.01
a
2.87 (1.4 to 5.9)
b < 0.01
b
Total parenteral nutrition Jordà-Marcos et al., 2007 [26]
a 3.89 (1.73 to 8.78) 0.001
Total parenteral nutrition Blumberg et al., 2001 [29] 3.6 (1.8 to 7.5) < 0.001
Total parenteral nutrition León et al., 2006 [27]
a 2.48 (1.16 to 5.31) < 0.001
Total parenteral nutrition Borzotta & Beardsley, 1999 [34] NR < 0.001
Fungal Colonisation
Digestive focus Ibàñez-Nolla et al., 2004 [31] 20.24 (6.11 to 67.03) < 0.001
Colonisation Index ≥ 0.5 Agvald-Ohman et al., 2008 [28] 19.1 (2.38 to 435) 0.017
Non-Candida albicans at screening Ibàñez-Nolla et al., 2004 [31] 11.68 (1.93 to 70.63) 0.007
Respiratory focus Ibàñez-Nolla et al., 2004 [31] 6.55 (1.25 to 34.3) 0.026
Candida colonisation Jordà-Marcos et al., 2007 [26]
a 4.12 (1.82 to 9.33) 0.001
Candida colonisation León et al., 2006 [27]
a 3.04 (1.45 to 6.39) < 0.001
Candida species corrected colonisation index Pittet et al., 1994 [33] 4.01 (2.16 to 7.45) < 0.001
Renal replacement therapy
Haemodialysis duration/days at risk Chow et al., 2008 [30] 3.84 (1.75 to 8.4)
a < 0.001
a
6.2 (2.67 to 14.4)
b < 0.0001
b
New-onset haemodialysis Paphitou et al., 2005 [35] 5.4 (2.5 to 11.8) 0.029
Haemofiltration Jordà-Marcos et al., 2007 [26]
a 1.96 (1.06 to 3.62) 0.032
Infection/sepsis
Hospital acquired Michalopoulos et al., 2003 [36] 9.4 (2.5 to 48.3) < 0.001
Severe sepsis León et al., 2006 [27]
a 7.68 (4.14 to 14.22) < 0.001
Enteric bacteraemia Chow et al., 2008 [30] 3.45 (1.38 to 8.63)
a < 0.01
a
3.43 (1.39 to 8.48)
b < 0.01
b
Mechanical ventilation
Mechanical ventilation > 10 days Michalopoulos et al., 2003 [36] 28.2 (3.6 to 119.5) < 0.001
Mechanical ventilation after day 3 McKinnon et al., 2001 [32] NR ≤ 0.05
Diabetes
Diabetes Paphitou et al., 2005 [35] 2.8 (1.6 to 4.7) 0.053
Diabetes Michalopoulos et al., 2003 [36] 2.4 (1.3 to 13.5) < 0.01
APACHE II or APACHE III score
APACHE II score Pittet et al., 1994 [33] 1.03 (1.01 to 1.05) 0.007
APACHE III score Ibàñez-Nolla et al., 2004 [31] 1.03 (1.00 to 1.06) 0.004
Cardiopulmonary bypass time > 120 min Michalopoulos et al., 2003 [36] 8.1 (2.9 to 23.6) < 0.01
Acute renal failure Blumberg et al., 2001 [29] 4.2 (2.1 to 8.3) < 0.001
Broad spectrum antibiotics Paphitou et al., 2005 [35] 3.0(1.8 to 5.0) 0.028
Red blood cell transfusion Chow et al., 2008 [30] 1.97 (0.98 to 3.99)
a 0.06
a
2.72 (1.33 to 5.58)
b < 0.01
b
Antifungal medication Blumberg et al., 2001 [29] 0.3 (0.1 to 0.6) < 0.001
Central venous catheters McKinnon et al., 2001 [32] NR ≤ 0.05
Diarrhoea McKinnon et al., 2001 [32] NR ≤ 0.05
Peripheral catheter use McKinnon et al., 2001 [32] NR ≤ 0.05
APACHE = Acute Physiology and Chronic Health Evaluation; CPB = cardiopulmonary bypass; NR = not reported. a = OR for outcomes in Candida albicans; b =O R
for outcomes in Candida non-albicans.
aData combined from both articles from the EPCAN Study.
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tivity and specificity of the model were 34% and 90%,
respectively.
Paphitou et al. [35] developed and validated a number
of clinical decision rules from a single-centre, retrospec-
tive cohort study of 327 critically ill patients comprising
9 cases of proven IFD and 27 probable or possible cases.
Several combinations of risk factors were evaluated, of
which any combination of diabetes mellitus, new-onset
haemodialysis, use of total parenteral nutrition or
receipt of broad-spectrum antibiotics was considered the
most useful. The model had a sensitivity of 78% to 83%
and specificity of approximately 50%.
Pittet et al. [33] developed a number of clinical deci-
sion rules based on intensity of Candida colonisation
from a single-centre, prospective cohort study of 29 cri-
tically ill patients with significant Candida colonisation,
of whom 11 had severe Candida infection. The best-
performing rule, developed post hoc to give perfect dis-
crimination in the small data set, was a Candida cor-
rected colonisation index (ratio of highly positive fungal
screening samples to the total number of samples) of
0.4 or more.
Piarroux et al. [38] evaluated the clinical decision rule
developed by Pittet et al. [33] whereby patients admitted
to a single surgical intensive care unit were screened for
fungal colonisation and preemptively treated with fluco-
nazole if the Candida corrected colonisation index was
0.4 or more. On the basis of a review of same-centre
historical controls from a time period prior to prophy-
laxis, a reduction of unit-acquired IFD from 2.2% to 0%
(P < 0.001) was reported.
Reporting of methodological assessment
The included studies varied with respect to their metho-
dological quality (Tables 5 and 6). All 12 studies
reported objectives, main outcomes and characteristics
of the selected study patients (Table 5). The majority of
the studies were carried out in at least two critical care
units. The analysis was defined ap r i o r iin ten (83%) of
the twelve studies, and the majority of known risk fac-
tors were accounted for in ten (91%) of the eleven stu-
dies in which multivariable analyses were conducted.
The study by Piarroux et al. [38] evaluated a clinical
decision rule and therefore did not carry out a risk fac-
tor analysis. Risk factors were poorly defined in over
Table 3 Comparison of studies for risk factors associated with invasive fungal disease
Risk factors Studies examining
risk factors (n)
Studies where risk factor was significantly
associated with IFD on univariable analysis (n)
Studies where risk factor was significantly
associated with IFD on multivariable analysis (n)
Surgery 7 5 5
Total parenteral
nutrition
66 4
Fungal
colonisation
54 4
Renal
replacement
therapy
75 3
Infection/sepsis 5 3 3
Mechanical
ventilation
52 2
Diabetes 4 3 2
APACHE II or
APACHE III score
82 2
Central venous
catheters
74 1
Broad-spectrum
antibiotics
85 1
CPB > 120
minutes
11 1
Red blood cell
transfusions
33 1
Antifungal
medication
42 1
Acute renal
failure
21 1
Diarrhoea 1 1 1
Peripheral
catheter
11 1
APACHE = Acute Physiology and Chronic Health Evaluation; CPB = cardiopulmonary bypass; IFD = invasive fungal disease.
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Study Development Validation Models/rules AUC Sensitivity Specificity PPV NPV
León et
al., 2006
[27]
Risk factors significant (P < 0.05)
on univariable analysis of full
sample included in multivariable
logistic regression model fitted in
65% development sample
Final model chosen by backward
elimination; stopping criterion
unclear
Simplified to bedside score by
rounding coefficients.
ROC and
sensitivity/
specificity at cut-off
values in 35%
validation sample
0.908 × (total parenteral
nutrition) + 0.997 × (surgery)
+ 1.112 × (multifocal Candida
species colonisation) + 2.038
× (severe sepsis)
0.847
(0.800
to
0.894)
NA NA NA NA
1 × (total parenteral nutrition)
+ 1 × (surgery) + 1 ×
(multifocal Candida species
colonisation) + 2 × (severe
sepsis)
NR NA NA NA NA
Bedside score ≥ 3, or,
equivalently, severe sepsis plus
at least one other risk factor or
all three other risk factors
NA 81% 74% NR NR
Ostrosky-
Zeichner
et al.,
2007 [37]
All rule development in 75%
development sample
Univariable analysis of risk factors
Clinical decision rules constructed
for ‘all possible combinations of
risk factors and time points’ in
‘several different formats (with
different weights for the risk
factors)’
’Best’ rules selected on sensitivity,
PPV, PPV/(1-NPV), and proportion
of patients identified as high risk
in development sample
c
2 test of
association,
sensitivity,
specificity, PPV and
NPV in 25%
validation sample
Any antibiotic days 1 to 3 and
CVC days 1 to 3
NA 89% 38% 4% 99%
Any antibiotic days 1 to 3)
and CVC days 1 to 3 and at
least one of the following:
Any surgery days -7 to 0
Immunosuppressive use days
-7 to 0
Pancreatitis days -7 to 0
TPN day 1-3; dialysis day 1-3
Steroid use days -7 to 3
NA 66% 69% 6% 98%
Any antibiotic days 1 to 3 or
CVC days 1 to 3 and at least
two of the following:
Any surgery days -7 to 0
Immunosuppressive use days
-7 to 0
Pancreatitis days -7 to 0
TPN days 1 to 3
Dialysis days 1 to 3
Steroid use days -7 to 3
NA 34% 90% 9% 97%
Paphitou
et al.,
2005 [35]
All rule development in full sample
Univariable analysis of risk factors;
unclear whether used to select
factors for multivariable model
Multivariable logistic regression
model with stepwise procedure;
unclear whether forward selection
or backward elimination and
unclear stopping criterion
Clinical decision rules constructed
‘using a combination of inspection
of the data and results of the
multivariable analysis’
Sensitivity and PPV
in full sample
NNT assuming 50%
relative reduction
in IFD associated
with treatment
Cost to prevent
one case assuming
prophylaxis $100/
day
At least one of the following:
Diabetes mellitus
TPN days -7 to 0
New-onset haemodialysis days
-7 to 3
NA 39% NR 17%
to
26%
NR
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Page 9 of 15half of the studies, and a rationale for inclusion was
missing in over two-thirds of the studies.
Reporting of the statistical modelling was generally
poor (Table 6), and it was usually impossible to deter-
mine exactly the number of variables that were consid-
ered as candidate predictors in each paper. Reported
methods often stated, for example, ‘Risk factors exam-
ined included...’, but it was not clear whether the sub-
sequent list was exhaustive, and risk factors could
often be determined only from those reported in the
results, which in some cases were only those selected
by a modelling process or only those that were statisti-
cally significant. The numbers of risk factors reported
in Table 6 are therefore approximate and, in many
cases, a minimum. Some studies split data into devel-
opment and validation samples, but did not report
how many of the events were in the development sam-
ple. However, even upon assessing the models on the
minimum number of variables included as indicated by
the report and the number of events in the full sample
(and therefore the maximum events per variable), all of
the papers had a strong likelihood of presenting results
that were overfitted to the data. Taking into account
all variables considered in the statistical modelling
(including those screened out on univariable analysis),
the largest studies had around four events per variable,
and a number of studies had examined at least as
many risk factors as there were events in the data set,
giving values of one event per variable or less. No stu-
dies reached the predefined threshold of ten events per
variable. Roughly half of the studies based their deci-
sion regarding which risk factors to include in their
multivariable analysis on univariable analysis, whereas
the reporting in the remaining studies was insufficient
to determine risk factor selection. In terms of model-
ling strategies, one-third of the studies used a forward
selection process, one-third used a backward elimina-
tion process, and for the remaining third, it was
unclear from the reporting which modelling strategy
was used.
Table 4 Studies developing risk models or clinical decision rules (Continued)
At least one of the following:
Diabetes mellitus
TPN days -7 to 0
New-onset haemodialysis days
-7 to 3
Broad-spectrum antibiotics
days -7 to 3
NA 78% to
83%
NR 11%
to
17%
NR
At least one of the following:
Diabetes mellitus
TPN days -7 to 0
New-onset haemodialysis days
-7 to 3
and
Broad-spectrum antibiotics
days -7 to 3
NA 30% to
33%
NR 20%
to
34%
NR
Pittet et
al., 1994
[33]
All rule development in full sample
Clinical decision rules constructed
from colonisation parameters only
(number of sites, colonisation
index, corrected colonisation index
derived post hoc); methods unclear
Risk factors with P < 0.15 on
univariable analysis included in
multivariable logistic regression
model
Only those with P < 0.05 in
multivariable model reported;
unclear if stepwise procedure used
Clinical decision
rules validated by
sensitivity,
specificity, PPV and
NPV in full sample
Colonisation at two or more
sites
NA 100% 22% 44% 100%
Colonisation at three or more
sites
NA 73% 56% 50% 77%
Colonisation at four or more
sites
NA 45% 72% 50% 68%
Candida colonisation index ≥
0.5
NA 100% 69% 66% 100%
Candida corrected colonisation
index ≥ 0.4
NA 100% 100% 100% 100%
AUC = area under the receiver operating characteristic curve; CVC = central venous catheter; IFD = invasive fungal disease; NA = not applicable; NNT = number
needed to treat to prevent one case; NPV = negative predictive value; NR = not reported; PPV = positive predictive value; ROC = receiver operating characteristic
curve; TPN = total parenteral nutrition.
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Thirteen articles were identified which investigated risk
factors, risk prediction models or clinical decisions rules
for invasive fungal disease in critically ill adult patients.
Of these 13, 8 articles examined risk factors specifically,
4 developed risk prediction models or clinical decision
rules and 1 evaluated a clinical decision rule.
In this systematic review, the following risk factors
were found in multiple studies to be significantly asso-
ciated with IFD: surgery, total parenteral nutrition, fungal
colonisation, renal replacement therapy, infection and
sepsis, mechanical ventilation, diabetes and APACHE II
or APACHE III score. Cardiopulmonary bypass time,
acute renal failure, broad-spectrum antibiotics, red blood
cell transfusion, antifungal medication, central venous
catheters, diarrhoea and peripheral catheter use were also
found to be statistically significant, but each in single stu-
dies only. The risk prediction model and clinical decision
rule studies employed all of the risk factors found to be
significant in multiple studies reported above, apart from
mechanical ventilation, and in addition included pancrea-
titis and immunosuppressant use. Risk factor definitions
varied across studies, with many studies offering no defi-
nition at all. Risk factor selection process and modelling
strategy also varied across studies, and no studies had an
adequate sample size for the multivariable analyses. None
of the selected studies described the degree of missing
data or of how missing data would be handled in the ana-
lysis. Some reported numbers of patients included in
each model, but reasons for exclusion were unclear.
The risk prediction models and clinical decision rules
identified in this review have a number of factors that
limit their usefulness for guiding early decision-making
regarding antifungal prophylaxis. First, with regard to
the patient populations studied, models and rules were
developed and evaluated using data from patients whose
length of stay in the critical care unit was four [35,37],
five [38] or seven days [27]. This would have helped to
identify high-risk populations; however, the performance
of these models and rules, if applied at an earlier time
point in the critical care stay, cannot be determined.
Some models and rules were developed on the basis of
patients with Candida colonisation only [27,33], and
consequently they could be used only to guide empiric
Table 5 Methodology and reporting assessment: general assessment
Study Is study
objective
clearly
described?
Are main
outcomes
measured
clearly
described?
Are patient
characteristics
clearly
described?
Was study
performed in
multiple centres
(more than two)?
Was
analysis
defined
a priori?
Did analysis
account for
majority of
known risk
factors?
Was rationale
behind inclusion
of risk factors
included?
Were risk
factors
clearly
defined?
Agvald-Ohman
et al., 2008 [28]
✓✓ ✓ xx x xx
Blumberg et
al., 2001 [29]
✓✓ ✓ ✓ ✓✓ xx
Borzotta &
Beardsley, 1999
[34]
✓✓ ✓ ✓ ✓✓ x ✓
Chow et al.,
2008 [30]
✓✓ ✓ ✓ ✓✓ xx
Ibàñez-Nolla et
al., 2004 [31]
✓✓ ✓ x ✓✓ xx
Jordà-Marcos
et al., 2007 [26]
✓✓ ✓ ✓ ✓✓ x ✓
León et al.,
2006 [27]
✓✓ ✓ ✓ ✓✓ x ✓
Michalopoulos
et al., 2003 [36]
✓✓ ✓ ✓ ✓✓ ✓ ✓
McKinnon et
al., 2001 [32]
✓✓ ✓ ✓ ✓✓ ✓ ✓
Ostrosky-
Zeichner et al.,
2007 [37]
✓✓ ✓ ✓ x ✓ xx
Paphitou et al.,
2005 [35]
✓✓ ✓ x ✓✓ ✓ x
Piarroux et al.,
2004 [38]
✓✓ ✓ x ✓ n/a n/a n/a
Pittet et al.,
1994 [33]
✓✓ ✓ xx ✓ x ✓
n/a = not applicable (evaluation of clinical decision rule, no risk factor analysis).
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Power Risk factor selection
a Statistical model
a
Article Events Variables EPV Were there ≥ 10
events per risk
factor?
All
Candidate
risk factors
used
Risk factors chosen based
on previous literature/
investigator choice
Risk factors chosen
based on
univariable analysis
Unclear No selection: all
variables kept in
model
Backward
elimination
Forward
selection
Unclear
Agvald-Ohman
et al., 2008 [28]
10 > 10 < 1 x ✓✓
Blumberg et
al., 2001 [29]
42 49 0.9 x ✓✓
Borzotta &
Beardsley, 1999
[34]
20 > 21 < 1 x ✓✓
Chow et al.,
2008 [30]
67
a
79
b
35 1.9
a
2.3
b
x ✓✓
Ibàñez-Nolla et
al., 2004 [31]
120 30 < 4 x ✓✓
Jordà-Marcos
et al., 2007 [26]
63 15 4.2 x ✓✓
León et al.,
2006 [27]
97 22 4.4 x ✓✓
Michalopoulos
et al., 2003 [36]
30 29 1.0 x ✓✓
McKinnon et
al., 2001 [32]
27 23 1.2 x ✓✓
Ostrosky-
Zeichner et al.,
2007 [37]
88 27 3.3 x ✓✓
Paphitou et al.,
2005 [35]
36 > 49 <
0.8
x ✓✓
Piarroux et al.,
2004 [38]
50 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Pittet et al.,
1994 [33]
11 9 1.2 x ✓✓
EPV = events per variable;
aevents/EPV for outcomes in Candida albicans;
bevents/EPV for outcomes in Candida non-albicans; a = most appropriate of the four options selected in each case; n/a = not applicable
(evaluation of clinical decision rule, no risk factor analysis).
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5therapy and not true prophylaxis. Second, with regard to
the statistical modelling, models are likely to be overfitted
because of the small number of events used for model
development. Stepwise selection of risk factors is likely to
have resulted in model coefficients that were too large
and measures of model performance that were optimistic
[39]. Despite having been developed in higher-risk popu-
lations identified by longer ICU stays, the specificity of
the rules was generally low and hence their use to guide
treatment could result in overuse of antifungal drugs,
with costs both financial and in terms of increased resis-
tance. No studies have adequately addressed the cost-
effectiveness of using clinical decision rules to guide
delivery of antifungal therapy. The only study that gave
any consideration to costs was that by Paphitou et al.
[35], who estimated the number needed to treat and
associated cost to prevent one case of IFD assuming a
relative risk of 0.5 and a cost of $100/day for antifungal
prophylaxis. The most promising rule on these criteria
had a number needed to treat of six to ten and an asso-
ciated cost of $12,000 to $21,000 per case prevented.
It is difficult to compare the performance of clinical
decision rules across the different studies, owing to the
variation in inclusion criteria, outcome definitions and
prevalence of the outcome. However, it should be noted
that the performance measures are likely to be favour-
ably biased because of overfitting to the data and lack of
external validation. Since the end date of our systematic
review, three studies have been published validating risk
prediction models or clinical decision rules identified in
this review. León et al. validated their risk prediction
model, the Candida Score [27], among a new prospec-
tive cohort of 892 admissions with Candida colonisation
with a stay of at least 7 days in one of 36 multidisciplin-
ary ICUs in Spain, Argentina and France [40]. As
expected, the performance of the score was not as good
in the validation sample with an area under the receiver
operating characteristic curve of 0.77 compared with
0.85 in the development data. Based on a cut-off of a
score of 3 or more, the sensitivity was 78% (81% in
development data), the specificity was 66% (74% in
development data) and positive and negative predictive
values were 14% and 98%, respectively (not reported in
development data). Playford et al. [41] validated four
clinical decision rules, the best rule from Ostrosky-
Zeichner et al. [37] and a subsequent revision of this
published in abstract form, and the two best rules from
Pittet et al. [33], in a prospective cohort of 615 patients
admitted for at least 72 hours to 4 multidisciplinary
ICUs in Australia. Performance of the clinical prediction
rules was worse than in the development data sets, and
the authors recommended that to identify a sufficiently
high risk population to consider for antifungal treatment
would require a combination of the clinical risk factors
from Ostrosky-Zeichner et al.[ 3 7 ] ,t o g e t h e rw i t hm e a -
sures of colonisation from Pittet et al.[ 3 3 ] .M o s t
recently, Hermsen et al. [42] set out to validate the clin-
ical decision rules of Paphitou et al. [35] and Ostrosky-
Zeichner et al. [37] in a case-control study of 88 cases
and 264 matched controls staying at least 4 days in a
single multidisciplinary ICU in the United States. Rather
than validate the rules as published, Hermsen et al.
fitted new conditional logistic regression models using
the risk factors from these rules, rendering their results
incomparable with the original publications. It is worth
noting, however, that a number of the risk factors
included in the rules (surgery, pancreatitis, haemodialy-
sis and diabetes) were not found to be significantly asso-
ciated with risk of IFD.
This review is the first to systematically evaluate and
assess the quality of the literature on risk factors for
IFD. Rigorous search methods and a tailored quality
assessment tool were combined to produce a high-qual-
ity systematic review. As search strategies are designed
for identifying randomised controlled trials rather than
risk factor studies, a comprehensive search strategy
including multiple medical subject heading terms and
keywords describing risk, risk prediction models and
clinical decision rules were employed. Furthermore,
abstracts and full-text articles were reviewed, and data
extracted, by two investigators independently to ensure
that all relevant articles and data were captured. There
is currently no validated gold standard or single recom-
mended instrument for methodological assessment of
risk factor studies, so a combined methodological assess-
ment was developed for this review and tailored to
assess the specific areas of risk factor studies which
were considered to be important.
One limitation of our review is that the heterogeneity
of the selected articles precluded any meta-analysis.
Study objectives differed between the studies, with some
assessing a specific clinical decision rule and some
examining a range of risk factors. The ways in which
the risk factors and outcomes were defined also differed,
and different inclusion criteria were imposed across the
studies, making combination of results inappropriate.
The existence of publication bias is always a possibility
in systematic reviews, but many risk factors were shown
to be nonsignificant on multivariable analysis, indicating
that negative as well as positive results were represented
in the studies. In the univariable analysis however, it
was difficult to identify which risk factors were non-
significant, as the full list of factors examined was not
always made clear.
Conclusions
In conclusion, this review has shown a number of risk
factors to be significantly associated with the
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Page 13 of 15development of IFD in critically ill adults. However, this
review has highlighted numerous methodological limita-
t i o n si nt h ed e s i g na n dc o n d u c to fs t u d i e si nt h i sa r e a ,
and as such it is suggested that caution should be used
in their interpretation. These results form an important
underpinning for a large, publicly funded, prospective
cohort study, the FIRE Study, which aims to develop
and validate a risk model to effectively target antifungal
prophylaxis to critically ill nonneutropenic patients at
high risk of IFD. The first step in model creation was to
prospectively gather data on risk factors and outcomes
for this patient group, which was guided by the results
of this review.
Key messages
◆ IFD in critically ill patients is associated with
increased morbidity and mortality at a cost to both
the individual and the healthcare system.
◆ Thirteen articles which investigated risk factors,
risk prediction models or clinical decisions rules for
IFD in critically ill adult patients were identified.
◆ Multiple risk factors were found to be associated
with IFD on univariable and multivariable analyses.
◆ Studies varied in terms of objectives, risk factors,
definitions and outcomes.
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